Home › Funds › Foresite Capital Management V, LLC › NRIX
Foresite Capital Management V, LLC position in NRIX
NURIX THERAPEUTICS INC · Health Care
Foresite Capital Management V, LLC reported holding 265,000 shares of NRIX (NURIX THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$6.4M, representing 1.77% of its reported portfolio and ranking #9 among its reported holdings. Foresite Capital Management V, LLC has disclosed NRIX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Foresite Capital Management V, LLC's NRIX position evolved
Foresite Capital Management V, LLC first disclosed a stake in NRIX in Q1 2026 at 265,000 shares (US$4.1M). The position peaked in Q2 2026 at 265,000 shares, worth US$6.4M. Across 2 filings, Foresite Capital Management V, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 265,000 shares valued at US$6.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 265.00K | $4.11M | New |
| Q2 2026 | 265.00K | $6.43M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NRIX and 13F data
NRIX (NURIX THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in NRIX — the largest reported positions include Vestal Point Capital, LP (US$195.3M), Deep Track Capital, LP (US$187.7M), Rubric Capital Management LP (US$175.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NRIX
- Vestal Point Capital, LP 8.05M sh · $195.29M · Q2 2026
- Deep Track Capital, LP 7.74M sh · $187.69M · Q2 2026
- Rubric Capital Management LP 7.23M sh · $175.35M · Q2 2026
- BAKER BROS. ADVISORS LP 4.66M sh · $113.02M · Q2 2026
- PERCEPTIVE ADVISORS LLC 4.32M sh · $104.81M · Q2 2026
- Redmile Group, LLC 4.07M sh · $98.83M · Q2 2026
- GENERAL ATLANTIC, L.P. 3.03M sh · $73.56M · Q2 2026
- Trails Edge Capital Partners, LP 1.57M sh · $38.17M · Q2 2026
- Soleus Capital Management, L.P. 1.47M sh · $35.54M · Q2 2026
- BRAIDWELL LP 1.29M sh · $31.22M · Q2 2026
- Kynam Capital Management, LP 1.19M sh · $28.98M · Q2 2026
- Affinity Asset Advisors, LLC 967.62K sh · $23.47M · Q2 2026
More on Foresite Capital Management V, LLC
FAQ
How long has Foresite Capital Management V, LLC held NRIX?
Foresite Capital Management V, LLC has disclosed NRIX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Foresite Capital Management V, LLC's current position in NRIX?
As of Q2 2026, Foresite Capital Management V, LLC holds 265.00K shares of NRIX (NURIX THERAPEUTICS INC), valued at $6.43M, representing 1.77% of its reported portfolio and ranking #9.
Has Foresite Capital Management V, LLC been buying or selling NRIX?
In the latest 13F filing (Q2 2026), Foresite Capital Management V, LLC held unchanged its position in NRIX. The position peaked in Q2 2026 at 265.00K shares.
Which other funds hold NRIX?
Other major institutional holders of NRIX include Vestal Point Capital, LP, Deep Track Capital, LP, Rubric Capital Management LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.